| Ytd | -20.23% | |
| 1y | 11.21% |
| Open | 6.36 | Prev Close | 6.39 | Low | 6.22 | High | 6.59 | Mkt Cap | 342.43M |
| Vol | 135.12K | Avg Vol | 193.30K | EPS | -0.72 | P/E | N/A | Forward P/E | -7.26 |
| Beta | 1.46 | Short Ratio | 3.88 | Inst. Own | 31.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 6.86 | 200-d Avg | 7.19 | 1yr Est | 7.00 |
DMAC News
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in Dia
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, wh
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 acr
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the a
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing no
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified I
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the an
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics (NASDAQ: DMAC) President and CEO Rick Pauls outlined the company's developmen
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the cl
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarte
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on dev
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing nov
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the an
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the a
Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Bu
Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and r
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) w
Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC)
Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM CentralDia